Cancer clinical trials in the region Pays de la Loire
413 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Multiple myeloma
#NCT05552222
#2022-000909-28
Required histologic types
Symptomatic multiple myeloma
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
9 recruiting sites
Janssen
Phase 3
Lung cancer
#NCT07291037
#2024-520101-39-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded genetic anomalies
ALK
BRAF
EGFR
HER2
KRAS G12C
MET
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
AstraZeneca
Phase 3
Multiple myeloma
#NCT06152575
#2023-507871-23-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Monoclonal antibodies
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
13 recruiting sites
Pfizer
Phase 3
Multiple myeloma
#NCT05243797
#2023-510384-36-00
Required histologic types
Symptomatic multiple myeloma
Required number of previous lines of therapy
None
Required previous treatments
Monoclonal antibodies
Autologous stem cell transplant
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
Car-T
9 recruiting sites
European Myeloma Network B.V.
Phase 3
Multiple myeloma
#NCT05623020
#2024-514139-50-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
3 recruiting sites
Pfizer
Phase 3
Multiple myeloma
#NCT05623020
#2024-514139-50-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
None
1
2
Required previous treatments
Systemic Treatment-Naive
Proteasome inhibitor
Immunomodulator
3 recruiting sites
Pfizer
Phase 3
Multiple myeloma
#NCT05827016
#2022-501515-14-00
Required histologic types
Symptomatic multiple myeloma
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Autologous stem cell transplant
Excluded previous treatments
Systemic Treatment-Naive
10 recruiting sites
Bristol-Myers Squibb
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06819007
#2024-516982-35-00
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Endometrioid carcinoma
Clear cell carcinoma
Mucinous carcinoma
Other epithelial ovarian cancer
Required FIGO stages
Stage III
Stage IV
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy
Targeted therapy
Excluded genetic anomalies
BRCA 1/2
10 recruiting sites
Daiichi Sankyo
Phase 3
Multiple myeloma
#NCT06158841
#2023-506668-15-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
2
3 or more
Required previous treatments
Monoclonal antibodies
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
2 recruiting sites
Abbvie
Phase 3
Amyloidosis
#NCT07207811
#2024-518899-31-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Cardiac
19 recruiting sites
Novo Nordisk A/S